Amneal Gains Approval for Erythromycin Tablets USP

Published: Mar 14, 2018

BRIDGEWATER, N.J., March 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available.

"Amneal is committed to increasing access to affordable medications," said Amneal EVP-Commercial Operations Andy Boyer. "Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options."

Amneal's erythromycin tablets are sold in 100-count bottles and are now available to wholesalers, distributors and direct to the trade.

Annual U.S. sales of erythromycin tablets were $84 million, according to January 2018 IQVIA™ market data.

About Amneal

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) announced on October 17, 2017 that they have entered into a definitive business combination agreement with the resulting combined company expected to create the 5th largest generics business (by gross revenue) in the United States. The transaction is expected to close in the first half of 2018.

For more information, visit amneal.com.

All trademarks listed in this release are property of their respective owners.
Product photo is available upon request.

    CONTACTS:


    Sales

    Andy Boyer

    Executive Vice President, Commercial
     Operations

    908.409.6891                         Business Development

    andy.boyer@amneal.com                Apurva Saraf

                                          Vice President, Global Strategy & Corporate
                                          Development

    Media                                631.742.7674

    Cheryl Lechok

                                         apurvas@amneal.com

    Media Relations

    203.613.1506

    mediarelations@amneal.com

 

 

 

View original content with multimedia: http://www.prnewswire.com/news-releases/amneal-gains-approval-for-erythromycin-tablets-usp-300613712.html

SOURCE Amneal Pharmaceuticals LLC

 

Back to news